J. Rodgers

Publications92
h-index27
Citations3,406
Highly Influential Citations112
Claim Author Page
Author pages are created from data sourced from our academic publisher partnerships and public sources.

Recommended Authors

  • S. Erickson-Viitanen
  • 97 Publications • 3,351 Citations
  • R. Klabe
  • 71 Publications • 2,073 Citations
  • A. Tefferi
  • 1,633 Publications • 83,769 Citations
  • L. Bacheler
  • 102 Publications • 4,451 Citations
  • Publications
  • Influence
Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms.
TLDR
In a mouse model of JAK2V617F(+) MPN, oral INCB018424 markedly reduced splenomegaly and circulating levels of inflammatory cytokines, and preferentially eliminated neoplastic cells, resulting in significantly prolonged survival without myelosuppressive or immunosuppression effects.
View on PubMed
Selective Inhibition of JAK1 and JAK2 Is Efficacious in Rodent Models of Arthritis: Preclinical Characterization of INCB028050
TLDR
Data suggest that fractional inhibition of JAK1 and JAK2 is sufficient for significant activity in autoimmune disease models, as assessed by improvements in clinical, histologic and radiographic signs of disease.
View on Publisher
Treatment methods for the remediation of nitroaromatic explosives.
View on PubMed
Metabolism, Excretion, and Pharmacokinetics of [14C]INCB018424, a Selective Janus Tyrosine Kinase 1/2 Inhibitor, in Humans
TLDR
In healthy subjects administered daily oral doses of unlabeled INCB018424, there were minimal differences in parent and metabolite concentrations between day 1 and day 10, indicating a lack of accumulation of parent or metabolites between single and multiple dosing.
View on Publisher
Preclinical evaluation of local JAK1 and JAK2 inhibition in cutaneous inflammation.
JAKs are required for signaling initiated by several cytokines (e.g., IL-4, IL-12, IL-23, thymic stromal lymphopoietin (TSLP), and IFNγ) implicated in the pathogenesis of inflammatory skin diseases…
View on PubMed
Downmodulation of key inflammatory cell markers with a topical Janus kinase 1/2 inhibitor
INCB018424 is a novel, potent Janus kinase (JAK)1/JAK2 inhibitor that blocks signal transduction of multiple proinflammatory cytokines.
View on Wiley
Inhibition of clinically relevant mutant variants of HIV-1 by quinazolinone non-nucleoside reverse transcriptase inhibitors.
TLDR
The increased potency of these NRTIs is combined with favorable plasma serum protein binding as demonstrated by improvements in the percent free drug in human plasma when compared to efavirenz.
View on PubMed
Electrochemical oxidation of chlorinated phenols
Electrochemical oxidation has been proposed as a remediation method for chlorinated phenols but is hampered by anode fouling. In this work we explore the mechanism of anode fouling by chlorinated…
View via Publisher
Expanded-Spectrum Nonnucleoside Reverse Transcriptase Inhibitors Inhibit Clinically Relevant Mutant Variants of Human Immunodeficiency Virus Type 1
ABSTRACT A research program targeted toward the identification of expanded-spectrum nonnucleoside reverse transcriptase inhibitors which possess increased potency toward K103N-containing mutant human…
View on ASMUSA
Enantioselective synthesis of Janus kinase inhibitor INCB018424 via an organocatalytic aza-Michael reaction.
An enantioselective synthesis of INCB018424 via organocatalytic asymmetric aza-Michael addition of pyrazoles (16 or 20) to (E)-3-cyclopentylacrylaldehyde (23) using diarylprolinol silyl ether as the…
View on PubMed
...
...